The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA

AIM: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, and is associated with high healthcare burden. We evaluated the cost–effectiveness of pegcetacoplan, a proximal complement-3 inhibitor (C3i), compared with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishman, Jesse, Wilson, Koo, Drzewiecka, Aleksandra, Pochopień, Michał, Dingli, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690430/
https://www.ncbi.nlm.nih.gov/pubmed/37655691
http://dx.doi.org/10.57264/cer-2023-0055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690430/
https://www.ncbi.nlm.nih.gov/pubmed/37655691
http://dx.doi.org/10.57264/cer-2023-0055

Ejemplares similares